BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 17031388)

  • 21. Effects of myosin heavy chain (MHC) plasticity induced by HMGCoA-reductase inhibition on skeletal muscle functions.
    Trapani L; Melli L; Segatto M; Trezza V; Campolongo P; Jozwiak A; Swiezewska E; Pucillo LP; Moreno S; Fanelli F; Linari M; Pallottini V
    FASEB J; 2011 Nov; 25(11):4037-47. PubMed ID: 21798954
    [TBL] [Abstract][Full Text] [Related]  

  • 22. HMG-CoA reductase inhibitor-induced myopathy in the rat: cyclosporine A interaction and mechanism studies.
    Smith PF; Eydelloth RS; Grossman SJ; Stubbs RJ; Schwartz MS; Germershausen JI; Vyas KP; Kari PH; MacDonald JS
    J Pharmacol Exp Ther; 1991 Jun; 257(3):1225-35. PubMed ID: 1904494
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of 90-day hypolipidemic treatment on insulin resistance, adipokines and proinflammatory cytokines in patients with mixed hyperlipidemia and impaired fasting glucose.
    Buldak L; Dulawa-Buldak A; Labuzek K; Okopien B
    Int J Clin Pharmacol Ther; 2012 Nov; 50(11):805-13. PubMed ID: 22943927
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of chronic growth hormone treatment in aged rats on the biophysical and pharmacological properties of skeletal muscle chloride channels.
    De Luca A; Pierno S; Cocchi D; Conte Camerino D
    Br J Pharmacol; 1997 Jun; 121(3):369-74. PubMed ID: 9179375
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Involvement of organic anion transporting polypeptides in the toxicity of hydrophilic pravastatin and lipophilic fluvastatin in rat skeletal myofibres.
    Sakamoto K; Mikami H; Kimura J
    Br J Pharmacol; 2008 Aug; 154(7):1482-90. PubMed ID: 18500364
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Isotretinoin and fenofibrate induce adiposity with distinct effect on metabolic profile in a rat model of the insulin resistance syndrome.
    Sedova L; Seda O; Krenova D; Kren V; Kazdova L
    Int J Obes Relat Metab Disord; 2004 May; 28(5):719-25. PubMed ID: 15007394
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Statin-induced myotoxicity is exacerbated by aging: A biophysical and molecular biology study in rats treated with atorvastatin.
    Camerino GM; De Bellis M; Conte E; Liantonio A; Musaraj K; Cannone M; Fonzino A; Giustino A; De Luca A; Romano R; Camerino C; Laghezza A; Loiodice F; Desaphy JF; Conte Camerino D; Pierno S
    Toxicol Appl Pharmacol; 2016 Sep; 306():36-46. PubMed ID: 27377005
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fenofibrate-induced muscular toxicity is associated with a metabolic shift limited to type-1 muscles in rats.
    Okada M; Sano F; Ikeda I; Sugimoto J; Takagi S; Sakai H; Yanai T
    Toxicol Pathol; 2009 Jun; 37(4):517-20. PubMed ID: 19395589
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Low dose simvastatin induces compositional, structural and dynamic changes in rat skeletal extensor digitorum longus muscle tissue.
    Simsek Ozek N; Sara Y; Onur R; Severcan F
    Biosci Rep; 2009 Oct; 30(1):41-50. PubMed ID: 19228123
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pre- and postnatal toxicity of the HMG-CoA reductase inhibitor atorvastatin in rats.
    Henck JW; Craft WR; Black A; Colgin J; Anderson JA
    Toxicol Sci; 1998 Jan; 41(1):88-99. PubMed ID: 9520344
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative neuroprotective profile of statins in quinolinic acid induced neurotoxicity in rats.
    Kalonia H; Kumar P; Kumar A
    Behav Brain Res; 2011 Jan; 216(1):220-8. PubMed ID: 20696189
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rab-small GTPases are involved in fluvastatin and pravastatin-induced vacuolation in rat skeletal myofibers.
    Sakamoto K; Honda T; Yokoya S; Waguri S; Kimura J
    FASEB J; 2007 Dec; 21(14):4087-94. PubMed ID: 17634390
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhibition of Rab1 GTPase and endoplasmic reticulum-to-Golgi trafficking underlies statin's toxicity in rat skeletal myofibers.
    Sakamoto K; Wada I; Kimura J
    J Pharmacol Exp Ther; 2011 Jul; 338(1):62-9. PubMed ID: 21467191
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nitric oxide prevents atorvastatin-induced skeletal muscle dysfunction and alterations in mice.
    D'Antona G; Mascaro A; Monopoli A; Miglietta D; Ongini E; Bottinelli R
    Muscle Nerve; 2013 Jan; 47(1):72-80. PubMed ID: 23042511
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Potential risk of myopathy by HMG-CoA reductase inhibitors: a comparison of pravastatin and simvastatin effects on membrane electrical properties of rat skeletal muscle fibers.
    Pierno S; De Luca A; Tricarico D; Roselli A; Natuzzi F; Ferrannini E; Laico M; Camerino DC
    J Pharmacol Exp Ther; 1995 Dec; 275(3):1490-6. PubMed ID: 8531120
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Statin-induced muscle necrosis in the rat: distribution, development, and fibre selectivity.
    Westwood FR; Bigley A; Randall K; Marsden AM; Scott RC
    Toxicol Pathol; 2005; 33(2):246-57. PubMed ID: 15902968
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of D-003, a mixture of long-chain aliphatic primary acids, fluvastatin and the combined therapy of D-003 plus fluvastatin on the lipid profile of normocholesterolemic rabbits.
    Mendoza S; Gamez R; Mas R; Goicochea E
    Int J Tissue React; 2003; 25(3):81-9. PubMed ID: 14756189
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of the efficacies of five different statins on inhibition of human saphenous vein smooth muscle cell proliferation and invasion.
    Turner NA; Midgley L; O'Regan DJ; Porter KE
    J Cardiovasc Pharmacol; 2007 Oct; 50(4):458-61. PubMed ID: 18049315
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and tolerability of atorvastatin/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: a 12-week, multicenter, double-blind, randomized, parallel-group study.
    Davidson MH; Rooney MW; Drucker J; Eugene Griffin H; Oosman S; Beckert M;
    Clin Ther; 2009 Dec; 31(12):2824-38. PubMed ID: 20110022
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High doses of atorvastatin (Sortis) modify the secretory process in the exocrine portion of the pancreas.
    Czerny K; Romanowska J; Kifer-Wysocka E; Matysiak W; Masłyk T
    Ann Univ Mariae Curie Sklodowska Med; 2004; 59(2):52-6. PubMed ID: 16146048
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.